Compare TOWN & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TOWN | RCKT |
|---|---|---|
| Founded | 1998 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 340.9M |
| IPO Year | 1999 | N/A |
| Metric | TOWN | RCKT |
|---|---|---|
| Price | $35.47 | $3.39 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 14 |
| Target Price | ★ $41.00 | $29.12 |
| AVG Volume (30 Days) | 315.8K | ★ 2.3M |
| Earning Date | 01-21-2026 | 11-06-2025 |
| Dividend Yield | ★ 3.05% | N/A |
| EPS Growth | ★ 11.95 | N/A |
| EPS | ★ 2.23 | N/A |
| Revenue | ★ $766,599,000.00 | N/A |
| Revenue This Year | $23.63 | N/A |
| Revenue Next Year | $29.20 | N/A |
| P/E Ratio | $15.89 | ★ N/A |
| Revenue Growth | ★ 14.10 | N/A |
| 52 Week Low | $29.43 | $2.19 |
| 52 Week High | $38.01 | $13.50 |
| Indicator | TOWN | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 69.02 | 52.07 |
| Support Level | $33.33 | $3.30 |
| Resistance Level | $35.68 | $3.65 |
| Average True Range (ATR) | 0.59 | 0.19 |
| MACD | 0.24 | 0.05 |
| Stochastic Oscillator | 93.73 | 66.22 |
Towne Bank is a financial services company that places special emphasis on serving the financial needs of individuals, commercial enterprises, and professionals, offering retail and commercial banking services to numerous markets in Virginia and North Carolina. The company has three reportable segments: the Banking Segment provides loan and deposit services to retail and commercial customers and provides commercial mortgage brokerage services and investment and asset management services, and the Realty Segment provides residential real estate services and mortgage loans. It also provides resort property management and residential and commercial title insurance, and the Insurance Segment provides a wide array of insurance products, including property, casualty, life, and health insurance.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.